The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes
Open accessAbstract
Inclusion of continuous glucose monitoring (CGM) targets for children, adolescents, and young adults <25 years. Adoption of a unified fingerstick capillary glucose (SMBG) target of between 4 and 10 mmol/L (70–180 mg/dl), which aligns with the target CGM time in range (TIR), while emphasizing a tighter fasting target range of 4–8 mmol/L (70–144 mg/dl). Recognition that disparities in the social determinants of health (SDOH) and inequitable access to modern diabetes therapies represent significant barriers to achieving glucose targets and optimizing clinical outcomes. Health stakeholders are responsible for addressing this disparity. Achieving target glucose levels assessed through CGM, HbA1c, and/or SMBG: Target HbA1c for young people with diabetes should be <53 mmol/mol (<7.0%) A CGM metrics, recorded over a 14-day period, should have time spent as follows: B Less stringent HbA1c, CGM, or SMBG targets are only advisable when achieving the standard target is assessed as being detrimental to the overall well-being of the person with diabetes or their caregivers. Factors to consider when setting a less stringent target include (but are not limited to): Glycemic targets for young people with diabetes are needed as optimizing glycemia reduces short and long-term complications.1, 2 In addition to protecting against micro- and macrovascular complications, of particular importance in pediatrics is the negative association of hypoglycemia and hyperglycemia on cognition and brain structure,3 especially in individuals with early onset diabetes.4 Further, the wider impact of diabetes on healthcare systems and health economics is an important driver to target better glycemic outcomes to prevent future complications.5, 6 Diabetes registries have shown steady improvement in median HbA1c levels in recent decades, yet only a minority of young people attain current glycemic targets.7 The improvements that have been demonstrated can be attributed to multiple factors, including how healthcare teams set and communicate glycemic targets, improved therapeutics (insulin analogs, CGM), highly skilled and knowledgeable workforce, and, recently, the use of automated insulin delivery systems. Nevertheless, social determinants of health, pediatric diabetes workforce constraints, and access to improved therapeutics remain significant barriers preventing more young people from reaching target glycemia, and further, drives health inequity.8, 9 Setting glycemic targets has been standard practice for diabetes organizations, including ISPAD, the American Diabetes Association (ADA), and the National Institute of Clinical Excellence (NICE) in the United Kingdom for 20 years, and have been regularly updated when evidence has supported change.10 For example, when different stakeholders published divergent HbA1c targets, and lower HbA1c targets were shown not to increase the rates of severe hypoglycemia,11 lower targets were adopted. It is important to recognize that setting targets contributes to improving glycemia as shown by the observation that a combination of setting a lower target HbA1c and consistency among members of teams within centers is associated with lower center HbA1c levels.11, 12 It is essential that target setting is a collaborative discussion with the person with diabetes (including caregivers) and health care professionals. Furthermore, prospective audit activity, involvement in data registries, and clinical benchmarking, including quality improvement implementation, are also associated with overall improvements in glycemic outcomes.13, 14 Health care professionals and people with diabetes now have a wide array of tools to assess glycemia, including self-monitored capillary blood glucose (SMBG) values, HbA1c, and CGM. While traditionally HbA1c has been the gold standard, there are limitations to this measurement as discussed later. Correspondingly, with rapidly increasing adoption of CGM, which arguably avoids these limitations, CGM metric reporting has been standardized and CGM metrics are included in this chapter. The recent COVID-19 global pandemic, and increased opportunities for the use of video or phone appointments between a person with diabetes and/or their carer and the health care professional, has highlighted the utility of CGM metrics to assess glycemia when laboratory measurement of HbA1c level is not available. While disparities also exist for accessing telemedicine including implicit bias, well-developed work plans can expand the population who can benefit from this health delivery method.15 Nevertheless, not all young people can access CGM and are reliant on SMBG and/or HbA1c measurement. Using all available forms of glycemic data, in combination if available, will give the most accurate account of glycemia to help guide therapy. Individualized glycemic target setting above the stated HbA1c target has been emphasized in recent consensus statements.16, 17 This was included to address concerns that for some youn
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
The Clinical Information Value of the Glycosylated Hemoglobin Assay
Nathan, D. M., Singer, D. E., Hurxthal, K., & Goodson, J. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402093100602 · Cited by 706
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604
Self-citationDiabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c
Cohen, R. M., Franco, R. S., Khera, P. K., Smith, E. P., Lindsell, C. J., Ciraolo, P. J., Palascak, M. B., & Joiner, C. H. (2008) · Blood · doi:10.1182/blood-2008-04-154112 · Cited by 478
Fructosamine: structure, analysis, and clinical usefulness.
Armbruster, D. A. (1987) · Clinical Chemistry · doi:10.1093/clinchem/33.12.2153 · Cited by 437
Review: Glycation of human serum albumin
Anguizola, J., Matsuda, R., Barnaby, O. S., Hoy, K. S., Wa, C., DeBolt, E., Koke, M., & Hage, D. S. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.07.013 · Cited by 395
Tahara, Y., & Shima, K. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.440 · Cited by 380
14. Children and Adolescents: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s014 · Cited by 367
Shah, V. N., DuBose, S. N., Li, Z., Beck, R. W., Peters, A. L., Weinstock, R. S., Kruger, D., Tansey, M., Sparling, D., Woerner, S., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02763 · Cited by 362
Yapanis, M., James, S., Craig, M. E., O’Neal, D., & Ekinci, E. I. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac034 · Cited by 291
Self-citationOptimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control
Riddlesworth, T. D., Beck, R. W., Gal, R. L., Connor, C. G., Bergenstal, R. M., Lee, S., & Willi, S. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0455 · Cited by 266
Influence of an Early-Onset Age of Type 1 Diabetes on Cerebral Structure and Cognitive Function
Ferguson, S. C., Blane, A., Wardlaw, J., Frier, B. M., Perros, P., McCrimmon, R. J., & Deary, I. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1431 · Cited by 253
2010 Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement
Hanas, R., John, G., & On behalf of the International HbA1c Consensus Committee (2010) · Diabetes Care · doi:10.2337/dc10-0953 · Cited by 227
1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions
Dungan, K. M. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.9 · Cited by 207
Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method
Tao, B., Pietropaolo, M., Atkinson, M., Schatz, D., & Taylor, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011501 · Cited by 197
Racial–Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes
Agarwal, S., Schechter, C., Gonzalez, J., & Long, J. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0338 · Cited by 182
Red cell age-related changes of hemoglobins AIa+b and AIc in normal and diabetic subjects.
Fitzgibbons, J. F., Koler, R. D., & Jones, R. T. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108534 · Cited by 166
Lachin, J. M., & Nathan, D. M. (2021) · Diabetes Care · doi:10.2337/dc20-3097 · Cited by 163
for the DPV Initiative and the T1D Exchange Clinic Network, Maahs, D. M., Hermann, J. M., DuBose, S. N., Miller, K. M., Heidtmann, B., DiMeglio, L. A., Rami-Merhar, B., Beck, R. W., Schober, E., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3272-2 · Cited by 159
Self-citationKarges, B., Rosenbauer, J., Kapellen, T. M., Wagner, V. M., Schober, E., Karges, W., & Holl, R. W. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001742 · Cited by 146
Swift, P. G. F., Skinner, T. C., de Beaufort, C. E., Cameron, F. J., Åman, J., Aanstoot, H., Castaño, L. A., Chiarelli, F., Daneman, D., Danne, T., et al. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00596.x · Cited by 139
Preserving Skin Integrity with Chronic Device Use in Diabetes
Messer, L. H., Berget, C., Beatson, C. R., Polsky, S., & Forlenza, G. P. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0080 · Cited by 125
Odugbesan, O., Addala, A., Nelson, G., Hopkins, R., Cossen, K., Schmitt, J. A., Indyk, J. A., Jones, N. Y., Agarwal, S., Rompicherla, S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0042 · Cited by 117
Rama Chandran, S., Tay, W. L., Lye, W. K., Lim, L. L., Ratnasingam, J., Tan, A. T. B., & S.L. Gardner, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0388 · Cited by 114
Addala, A., Hanes, S. J., Naranjo, D. M., Maahs, D. M., & Hood, K. K. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211006476 · Cited by 111
Self-citationHbA1c and Glucose Management Indicator Discordance: A Real-World Analysis
Perlman, J. E., Gooley, T. A., MCNULTY, B. K., Meyers, J., & Hirsch, I. B. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0501 · Cited by 107
Lipman, T. H., & Hawkes, C. P. (2020) · Diabetes Care · doi:10.2337/dci20-0048 · Cited by 103
Asarani, N. A. M., Reynolds, A. N., Styles, S. E., de Bock, M. I., & Wheeler, B. J. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819870849 · Cited by 98
REDONDO, M. J., Libman, I. M., Maahs, D. M., Lyons, S. K., Saraco, M., Reusch, J. E. B., Rodriguez, H., & DiMeglio, L. A. (2021) · Diabetes Care · doi:10.2337/dc20-1978 · Cited by 92
Self-citationJohnson, S. R., Holmes-Walker, D. J., Chee, M., Earnest, A., & Jones, T. W. (2022) · Diabetes Care · doi:10.2337/dc21-1666 · Cited by 86
National diabetes registries: do they make a difference?
Bak, J. C. G., Serné, E. H., Kramer, M. H. H., Nieuwdorp, M., & Verheugt, C. L. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01576-8 · Cited by 86
Prahalad, P., Ding, V. Y., Zaharieva, D. P., Addala, A., Johari, R., Scheinker, D., Desai, M., Hood, K., & Maahs, D. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab859 · Cited by 82
Self-citationEstablishment of the T1D Exchange Quality Improvement Collaborative (T1DX-QI)
Alonso, G. T., Corathers, S. D., Shah, A. C., Clements, M. A., Kamboj, M. K., Sonabend, R., DeSalvo, D. J., Mehta, S. N., CABRERA, A. B., Rioles, N. A., et al. (2020) · Clinical Diabetes · doi:10.2337/cd19-0032 · Cited by 78
Anderzén, J., Hermann, J. M., Samuelsson, U., Charalampopoulos, D., Svensson, J., Skrivarhaug, T., Fröhlich-Reiterer, E. E., Maahs, D. M., Åkesson, K., Kapellen, T. M., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13014 · Cited by 68
Self-citationNevo-Shenker, M., & Shalitin, S. (2021) · Hormone Research in Paediatrics · doi:10.1159/000517352 · Cited by 67
Mulinacci, G., Alonso, G. T., Snell-Bergeon, J. K., & Shah, V. N. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0257 · Cited by 66
Lachin, J. M., Bebu, I., & Nathan, D. M. (2021) · Diabetes Care · doi:10.2337/dc21-1331 · Cited by 59
The Cost of Diabetes-Related Complications: Registry-Based Analysis of Days Absent from Work
Sørensen, J. R., & Ploug, U. J. (2013) · Economics Research International · doi:10.1155/2013/618039 · Cited by 58
Continued improvement of metabolic control in Swedish pediatric diabetes care
Samuelsson, U., Åkesson, K., Peterson, A., Hanås, R., & Hanberger, L. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12467 · Cited by 55
Nirantharakumar, K., Mohammed, N. I., Toulis, K. A., Thomas, G. N., & Narendran, P. (2018) · Diabetologia · doi:10.1007/s00125-018-4574-6 · Cited by 48
Pleus, S., Ulbrich, S., Zschornack, E., Kamann, S., Haug, C., & Freckmann, G. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0171 · Cited by 47
Sofizadeh, S., Pehrsson, A., Ólafsdóttir, A. F., & Lind, M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820965599 · Cited by 37
Miller, E. M., & Midyett, L. K. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0192 · Cited by 21
Challenges of Diabetes Management in Toddlers
Deeb, A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0130 · Cited by 20
Cited by
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Metadata
- Authors
- de Bock, M., Codner, E., Craig, M. E., Huynh, T., Maahs, D. M., Mahmud, F. H., Marcovecchio, L., & DiMeglio, L. A.
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2022-12
- Volume
- 23
- Issue
- 8
- Pages
- 1270-1276
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W4312179373
- Cited by
- 254
- References
- 51
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.